Alembic Pharmaceuticals has posted impressive financial performance during the first quarter ended June 2016 and its net profit went up by 44.6 per cent to Rs.103.75 crore from Rs.71.73 crore. EBDITA also moved up 50.8 per cent to Rs.157.35 crore from Rs.104.35 crore. With strong growth in bottom line, EPS jumped to Rs.5.41 from Rs.3.72 in the last period. Its R&D expenditure increased by 65.7 per cent to Rs.79.46 crore from Rs.47.95 crore.
Pranav Amin, managing director, said, “We continue to invest in R&D for future growth. Alembic USA was successfully established and has launched 23 products in the market.”
Alembic's international formulation business grew by 72 per cent to Rs.308 crore and it launched 23 products in US. It filed 2 ANDA and cumulative filings reached at 78 ANDAs. Similarly, it filed one DMF and cumulative DMF filing reached at 82 products.
Its Indian branded formulation business improved by 6 per cent to Rs.278 crore of which specialty segment moved up by 16 per cent. Its Indian generic sales, however, declined by 23 per cent to Rs.21.32 crore from Rs.27.80 crore.